Windlas Biotech IPO: Know the grey market premium and its marquee customers

Windlas Biotech Ltd, one of the leading market players in the domestic pharmaceutical formulation or CDMO segment, is set for it's IPO. Windlas has got Rs 120.46 crore from 22 anchor investors ahead of IPO, but should a retail investor chip in here are the details of the issue -:

• IPO dates: August 4 to 6
• IPO price band: Rs 448 to 460/share
• Lot size: 30 shares
• Min. investment: Rs 13,800
• Grey market premium: Rs 130/share
• Issue size: Rs 400 crore

Founded in the year 2001, Windlas Biotech provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.

Leading pharma companies like Pfizer and Cadila are some of the marquee customers of Windlas Biotech.